← SynDRA
CANGRELOR
SynDRA canonical compound SYN0004605 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | P2RY12 |
|---|
| Mechanism of action | purinergic receptor antagonist |
|---|
| Indication | myocardial infarction |
|---|
| Disease area | cardiology |
|---|
All known targets
Mechanisms of action (all sources)
- P2RY12 ANTAGONIST
- Purinergic receptor P2Y12 antagonist
- P2RY12 INHIBITOR
- Purinergic receptor P2Y12 inhibitor
- purinergic receptor antagonist
Drug classes
- Hematologic Agents
- Neurotransmitter Agents
- Platelet Aggregation Inhibitors
- Purinergic Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic P2Y Receptor Antagonists
- P2Y12 Platelet Inhibitor
- P2Y12 Receptor Antagonists
ATC classes
- B01A · ANTITHROMBOTIC AGENTS
Cross-references
Synonyms
- canegrelor
- cangrelor tetrasodium
- kengreal
- AR-C69931XX
- AR-C69931MX
- kengrexal
- ARL69931
- Kengreal
- UNII-6AQ1Y404U7
- CHEMBL334966
- 6AQ1Y404U7
- 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine
- 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)
- CHEBI:90841
- cangrelorum
- RefChem:57346
- DTXCID8090142
- B01AC25
- Cangrelor free acid
- AR-C 69931
- Cangrelor; Kengreal
- Cangrelor [USAN:INN:BAN]
- Cangrelor free acid?
- CANGRELOR [INN]
- CANGRELOR [MI]
- Cangrelor (USAN/INN)
- CANGRELOR [USAN]
- CANGRELOR [WHO-DD]
- GTPL1776
- orb1739145
- SCHEMBL6113860
- CANGRELOR [ORANGE BOOK]
- ARL 69931MX
- HSDB 8489
- PAEBIVWUMLRPSK-IDTAVKCVSA-N
- GLXC-02798
- BDBM50118225
- EBC-27461
Reported adverse events
- Hypersensitivity
- Coronary artery dissection
Look up CANGRELOR in the interactive SynDRA portal →